"Our registry currently includes different haematological malignancies and we are very much looking forward to collaborating with Janssen and other HONEUR members, so that we can make significant inroads in improving treatments for patients with these rare blood diseases."

Prof. MUDr. Roman Hájek, CSc. (Haematology), The Registry of Monoclonal Gammopathies (RMG), Czech Republic
HONEUR Board member

"My colleagues and I at the Leicester Royal Infirmary are passionate about the development and use of database records in haematological disorders, as they provide a source of invaluable information for benchmarking, education and research purposes. Joining HONEUR brings us a big step closer to generating Real-World Data that ultimately has a meaningful impact on patients."

Dr. Mamta Garg, Consultant Haematologist, MD, FRCP, FRCPath, Leicester Royal Infirmary, United Kingdom
HONEUR Board member

"As a long-standing and trusted partner in the HONEUR network, TriNetx has been collaborating with Johnson&Johnson Innovative Medicine in the strive to establish real-world evidence as a crucial source in cancer research. We are proud to support the HONEUR research network with data from a very large and granular Multiple Myeloma Database in Europe. Joining forces with leading hematologists, HONEUR’s team of experts and further research organizations, we are excited to generate significant, current and collaborative insights contributing to the development of Multiple Myeloma treatments."

Andreas Weber, Senior Vice President TriNetX Oncology

"I am really proud to be part of HONEUR, primarily because of the possibility to share ideas with some of the most important key opinion leaders in hematologic malignancies, particularly Multiple Myeloma, but also to have the direct opportunity to propose potential new studies and analysis that could answer to up-to-date questions.

A European Federated Data Network such as HONEUR could also facilitate the comparison of real-world management of blood malignancies across different countries. This could support the identification of treatment variations to optimize patient opportunities, enhance outcomes, and better integrate innovative therapies into clinical practice."

Prof. Claudio Cerchione, MD, PhD, Hematology Unit, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS
HONEUR Board member